Allogene Therapeutics develops engineered T cell treatments from healthy donor cells for cancer and autoimmune diseases. It last closed at $0.63 on Nov 20, down 5.88% on the day. The next earnings report for ALLO is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, ALLO reported EPS of -$0.15 on revenue of $0. Over its last 8 reports the stock moved an average of 6.7% the session after earnings. Over the last 12 months ALLO insiders bought $0 of stock on the open market and sold $668K, according to SEC Form 4 filings.
AI Auto Pilots
Is ALLO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ALLO.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on ALLOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
ALLO · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 58% below its 20 day and 107% below its 50 day average. It is 206% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 17), oversold. The nearest support is the 52 week low at $0.62, and the nearest resistance the Pivot at $0.64.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 14.1%/day
Key levels
$4.4652 week high+607.9%
$1.92200 day average+204.8%
$1.63100 day average+158.7%
$1.36Swing high (Oct 21)+115.9%
$1.3050 day average+106.3%
$0.9920 day average+57.1%
$0.66Pivot R1+4.8%
$0.64Pivot+1.6%
$0.63Last close
$0.6252 week low−1.6%
$0.61Pivot S1−3.2%
Indicators
RSI (14)
17.04
Oversold below 30
Oversold
MACD
-0.19
Below its signal line
Bearish
Stochastic
2.0
Near the bottom of its range
Oversold
ADX (14)
52.8
Strong downtrend
Williams %R
-98.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-131.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−39.6%
Change over 10 sessions
Bearish
ATR (14)
$0.09
Typical daily range, 14.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 41.3%/day
Key levels
$4.4652 week high+607.9%
$1.92200 day average+204.8%
$1.63100 day average+158.7%
$1.36Swing high (Oct 21)+115.9%
$1.3050 day average+106.3%
$0.9920 day average+57.1%
$0.66Pivot R1+4.8%
$0.64Pivot+1.6%
$0.63Last close
$0.6252 week low−1.6%
$0.61Pivot S1−3.2%
Indicators
RSI (14)
21.43
Oversold below 30
Oversold
MACD
-0.28
Below its signal line
Bearish
Stochastic
2.2
Near the bottom of its range
Oversold
ADX (14)
28.7
Trending down
Williams %R
-99.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-179.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−64.7%
Change over 10 sessions
Bearish
ATR (14)
$0.26
Typical daily range, 41.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALLO
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ALLO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow ALLO usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for ALLOHow many large options trades hit ALLO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in ALLO in the last 90 days.
From SEC Form 4 filings by ALLO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALLO is in one of them and how their past ALLO trades turned out.
Allogene Therapeutics is a biotechnology company based in South San Francisco, California, that develops engineered T cell treatments for cancer and autoimmune diseases. Its treatments are made from healthy donor cells, so they can be prepared ahead of time and given to any eligible patient rather than made from each patient's own cells. Its main candidates target lymphoma, kidney cancer and autoimmune conditions such as lupus, and they are in clinical trials with patients as the intended users.